NASDAQ:SBFM Sunshine Biopharma (SBFM) Stock Price, News & Analysis $0.82 -0.02 (-2.93%) Closing price 04:00 PM EasternExtended Trading$0.82 0.00 (-0.11%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Sunshine Biopharma Stock (NASDAQ:SBFM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sunshine Biopharma alerts:Sign Up Key Stats Today's Range$0.82▼$0.8550-Day Range$0.80▼$1.8152-Week Range$0.78▼$24.30Volume37,374 shsAverage Volume723,750 shsMarket Capitalization$3.53 millionP/E RatioN/ADividend YieldN/APrice Target$70.00Consensus RatingHold Company Overview Sunshine Biopharma, Inc. (NASDAQ:SBFM) is a pharmaceutical and biotechnology company focused on the development of therapies for cancer and other serious diseases. Its research and development activities are centered on proprietary drug candidates intended to address unmet medical needs. The company’s lead oncology candidate is Adva-27a, a small-molecule topoisomerase II inhibitor being investigated for potential use against advanced solid tumors, including certain cancers that may be resistant to existing treatments. Sunshine Biopharma has also described research involving mRNA-based therapeutic approaches and treatments targeting coronaviruses. In addition to its biotechnology pipeline, Sunshine Biopharma has pursued pharmaceutical commercialization activities in Canada through its Canadian operations, which are associated with the distribution and sale of prescription and over-the-counter products. The company is headquartered in Montreal, Quebec, and has been led by founder and Chief Executive Officer Dr. Steve N. Slilaty.AI Generated. May Contain Errors. Read More Sunshine Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreSBFM MarketRank™: Sunshine Biopharma scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingSunshine Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialSunshine Biopharma has a consensus price target of $70.00, representing about 8,458.5% upside from its current price of $0.82.Amount of Analyst CoverageSunshine Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Sunshine Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sunshine Biopharma are expected to grow in the coming year, from ($1.95) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sunshine Biopharma is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sunshine Biopharma is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSunshine Biopharma has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sunshine Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.61% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently decreased by 73.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSunshine Biopharma does not currently pay a dividend.Dividend GrowthSunshine Biopharma does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.97 News SentimentSunshine Biopharma has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sunshine Biopharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.48% of the stock of Sunshine Biopharma is held by insiders.Percentage Held by Institutions41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sunshine Biopharma's insider trading history. Receive SBFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SBFM Stock News HeadlinesA Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityAugust 26, 2026 | markets.businessinsider.comEXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug ApprovalAugust 4, 2026 | benzinga.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.September 28 at 1:00 AM | Banyan Hill Publishing (Ad)Sunshine Biopharma Inc.: Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and VomitingJuly 30, 2026 | finanznachrichten.deSunshine Biopharma Inc.: Sunshine Biopharma and University of Arizona Publish Significant New Research FindingsJuly 20, 2026 | finanznachrichten.deSBFM Share News TodayMay 15, 2026 | uk.investing.comSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comSunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comSee More Headlines SBFM Stock Analysis - Frequently Asked Questions How have SBFM shares performed this year? Sunshine Biopharma's stock was trading at $12.30 on January 1st, 2026. Since then, SBFM shares have decreased by 93.4% and is now trading at $0.8179. How were Sunshine Biopharma's earnings last quarter? Sunshine Biopharma, Inc. (NASDAQ:SBFM) released its quarterly earnings results on Thursday, August, 13th. The company reported ($1.15) EPS for the quarter, topping analysts' consensus estimates of ($1.20) by $0.05. The company earned $9.26 million during the quarter, compared to the consensus estimate of $8.70 million. Sunshine Biopharma had a negative trailing twelve-month return on equity of 26.36% and a negative net margin of 17.94%. When did Sunshine Biopharma's stock split? Sunshine Biopharma shares reverse split before market open on Wednesday, April 17th 2024.The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Sunshine Biopharma? Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sunshine Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/13/2026Today9/28/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (56m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SBFM's financial health is in the Red zone, according to TradeSmith. SBFM has been in this zone for over 56 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SBFM CIK1402328 Webwww.sunshinebiopharma.com Phone(514) 426-6161FaxN/AEmployees50Year Founded2006Price Target and Rating Average Price Target for Sunshine Biopharma$70.00 High Price Target$70.00 Low Price Target$70.00 Potential Upside/Downside+8,458.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($10.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.97 million Net Margins-17.94% Pretax Margin-15.73% Return on Equity-26.36% Return on Assets-20.60% Debt Debt-to-Equity RatioN/A Current Ratio5.46 Quick Ratio3.30 Sales & Book Value Annual Sales$36.31 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value$46.93 per share Price / Book0.02Miscellaneous Outstanding Shares4,310,000Free Float4,289,000Market Cap$3.53 million OptionableNot Optionable Beta1.17 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SBFM) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SBFM Stock Alerts